<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>Molecular Diversity Preservation International</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M657</article-id>
      <article-id pub-id-type="publisher-id">molbank-2010-M657</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>5-Methyl-4-oxo-4,6-dihydro-3<italic>H</italic>-pyridazino[4,5-<italic>b</italic>]carbazole-1-carbonitrile</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Emich</surname>
            <given-names>Miriam</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Haider</surname>
            <given-names>Norbert</given-names>
          </name>
          <xref rid="c1-molbank-2010-M657" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2010-M657">Department of Drug and Natural Product Synthesis, Faculty of Life Sciences, University of Vienna, Althanstra&#xDF;e 14, A-1090 Vienna, Austria</aff>
      <author-notes>
        <corresp id="c1-molbank-2010-M657"><label>*</label> Author to whom correspondence should be addressed; E-Mail: <email>norbert.haider@univie.ac.at</email>.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>03</day>
        <month>02</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>03</month>
        <year>2010</year>
      </pub-date>
      <volume>2010</volume>
      <issue>1</issue>
      <elocation-id>M657</elocation-id>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>01</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>01</day>
          <month>02</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.</copyright-statement>
        <copyright-year>2010</copyright-year>
        <license>
          <p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>The title compound was prepared in excellent yield from 5-methyl-4-oxo-4,6-dihydro-3<italic>H</italic>-pyridazino[4,5-<italic>b</italic>]carbazole-1-carbaldehyde by treatment with hydroxylamine hydrochloride in formic acid without isolation of the intermediate oxime.</p>
      </abstract>
      <kwd-group>
        <kwd>pyridazino[4,5-<italic>b</italic>]carbazole</kwd>
        <kwd>oxime dehydration</kwd>
        <kwd>nitrile synthesis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
      <p>In a recent communication [<xref ref-type="bibr" rid="B1-molbank-2010-M657">1</xref>], we reported the synthesis of 5-methyl-4-oxo-4,6-dihydro-3<italic>H</italic>-pyridazino[4,5-<italic>b</italic>]carbazole-1-carbaldehyde (<bold>1</bold>) by oxidation of the corresponding hydroxymethyl precursor [<xref ref-type="bibr" rid="B2-molbank-2010-M657">2</xref>] with a hypervalent iodine reagent. Such functionalised tetracyclic pyridazines are of interest as aza analogues of the pyrido[4,3-<italic>b</italic>]carbazole alkaloids, <italic>ellipticine</italic> and <italic>olivacine</italic> [<xref ref-type="bibr" rid="B3-molbank-2010-M657">3</xref>,<xref ref-type="bibr" rid="B4-molbank-2010-M657">4</xref>,<xref ref-type="bibr" rid="B5-molbank-2010-M657">5</xref>] and related antitumor agents. The synthesis and anticancer activity of polycyclic nitrogen heterocycles of this and other types has been a major subject in our department&#x2019;s recent research activities [<xref ref-type="bibr" rid="B6-molbank-2010-M657">6</xref>,<xref ref-type="bibr" rid="B7-molbank-2010-M657">7</xref>,<xref ref-type="bibr" rid="B8-molbank-2010-M657">8</xref>,<xref ref-type="bibr" rid="B9-molbank-2010-M657">9</xref>,<xref ref-type="bibr" rid="B10-molbank-2010-M657">10</xref>,<xref ref-type="bibr" rid="B11-molbank-2010-M657">11</xref>].</p>
      <p>In order to extend our library of pyridazino[4,5-<italic>b</italic>]carbazole derivatives, the aldehyde <bold>1</bold> was chosen for further functionalisation at position 1 of the tetracyclic system. Whereas the aldehyde functionality, in principle, offers a wide variety of derivatisation options, the very low solubility of such fused pyridazinones in common organic solvents represents a challenge with respect to compound handling, work-up, and purification. Transformation into a carbonitrile was envisaged, as it would furnish a stable carboxylic acid derivative offering high flexibility with respect to further derivatisation. Initial attempts to effect the desired transformation of the aldehyde into the nitrile <italic>via</italic> the corresponding oxime in two consecutive steps gave unsatisfactory results. However, we found that the target nitrile (<bold>2</bold>) can be prepared very efficiently by treatment of the aldehyde with hydroxylamine hydrochloride in refluxing formic acid in the presence of a catalytic amount of concentrated sulfuric acid, applying a one-pot protocol previously reported by Bertini <italic>et al.</italic> [<xref ref-type="bibr" rid="B12-molbank-2010-M657">12</xref>]. The product, in this case, can be isolated very conveniently by dilution of the reaction mixture with water, followed by filtration of the precipitate. The structure of compound <bold>2</bold> thus obtained in 95% yield is clearly evident from its spectral data. The IR spectrum shows a nitrile absorption band at 2,240 cm<sup>-1</sup>. In the <sup>1</sup>H NMR spectrum, the aldehydic proton is no longer detectable and in the <sup>13</sup>C NMR spectrum the aldehyde carbon signal (at 191.9 ppm) had disappeared in favour of a resonance at 114.7 ppm, which is typical for the nitrile carbon atom.
	  <disp-formula>
        <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2010-M657-i001.tif"/>
      </disp-formula></p>
    <sec sec-type="methods">
      <title>Experimental</title>
      <p>The melting point was determined on a Kofler hot-stage microscope (Reichert) and is uncorrected. The IR spectrum was recorded on a Perkin-Elmer Spectrum 1000 instrument, <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Varian UnityPlus 300 spectrometer. The low-resolution mass spectrum was obtained on a Shimadzu QP5050A DI 50 instrument, the HR-MS was recorded on a Finnigan MAT 8230 at the Institute of Organic Chemistry, University of Vienna.</p>
      <sec>
        <title>5-Methyl-4-oxo-4,6-dihydro-3H-pyridazino[4,5-b]carbazole-1-carbonitrile <italic>(<bold>2</bold>)</italic></title>
        <p>To a suspension of 5-methyl-4-oxo-4,6-dihydro-3<italic>H</italic>-pyridazino[4,5-<italic>b</italic>]carbazole-1-carbaldehyde (<bold>1</bold>) [<xref ref-type="bibr" rid="B1-molbank-2010-M657">1</xref>] (100 mg, 0.37 mmol) in formic acid (2 mL) was added hydroxylamine hydrochloride (149 mg, 0.55 mmol) and one drop of concentrated sulfuric acid. The mixture was refluxed for 16 h, then it was cooled to room temperature and diluted with water (6 mL). The precipitate was collected by filtration, washed with water, and dried to afford the nitrile <bold>2</bold> as brownish crystals, m.p. &gt; 300 &#xB0;C (decomp.); yield: 97 mg (95%).</p>
        <p>IR (KBr): 3362, 3171, 2240, 1648, 1501, 1376, 1265, 1235, 1107, 750 cm<sup>-1</sup>.</p>
        <p>MS (EI, 70 eV): <italic>m/z</italic> = 275 (19%), 274 (M<sup>+</sup>, 100), 218 (18), 217 (12), 216 (11), 191 (21), 82 (11).</p>
        <p><sup>1</sup>H NMR (DMSO-<italic>d</italic><sub>6</sub>, 300 MHz): &#x3B4; = 3.15 (3H, s, 5-CH<sub>3</sub>), 7.29&#x2013;7.35 (1H, m, 9-H), 7.57&#x2013;7.67 (2H, m, 7-H, 8-H), 8.48 (1H, d, <italic>J</italic> = 8.1 Hz, 10-H), 8.58 (1H, s, 11-H), 12.02 (1H, s, carbazole-NH), 12.99 (1H, s, pyridazinone-NH).</p>
        <p><sup>13</sup>C NMR (DMSO-<italic>d</italic><sub>6</sub>, 75 MHz): &#x3B4; = 15.1 (5-CH<sub>3</sub>), 111.6, 113.9, 114.7 (nitrile-C), 120.0, 120.6, 120.8, 121.4, 121.9, 122.2, 123.9, 126.4, 128.5, 141.6, 141.8, 160.8 (4-C).</p>
        <p>HR-MS Calcd. for C<sub>16</sub>H<sub>10</sub>N<sub>4</sub>O: 274.0855. Found: 274.0851.</p>
      </sec>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="app1-molbank-2010-M657">
        <title>Supplementary materials</title>
        <supplementary-material id="molbank-2010-M657-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2010-M657-s001-mod.mol"><label>Supplementary File 1</label></supplementary-material>
        <supplementary-material id="molbank-2010-M657-s002" xmlns:xlink=  "http://www.w3.org/1999/xlink" xlink:href="molbank-2010-M657-s001.mol"><label>Supplementary File 2</label></supplementary-material>
      </app>
    </app-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We are grateful to Ing. P. Unteregger for recording the high-resolution mass spectrum.</p>
    </ack>
    <ref-list>
      <title>References and Notes</title>
      <ref id="B1-molbank-2010-M657">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emich</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Haider</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>5-Methyl-4-oxo-4,6-dihydro-3<italic>H</italic>-pyridazino[4,5-<italic>b</italic>]carbazole-1-carbaldehyde</article-title>
          <source>Molbank</source>
          <year>2009</year>
          <volume>2009</volume>
          <fpage>M623</fpage>
          <pub-id pub-id-type="doi">10.3390/M623</pub-id>
        </citation>
      </ref>
      <ref id="B2-molbank-2010-M657">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haider</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Sotelo</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>1,5-Dimethyl-6<italic>H</italic>-pyridazino[4,5-b]carbazole, a 3-aza bioisoster of the antitumor alkaloid olivacine</article-title>
          <source>Chem. Pharm. Bull.</source>
          <year>2002</year>
          <volume>50</volume>
          <fpage>1479</fpage>
          <lpage>1483</lpage>
          <pub-id pub-id-type="doi">10.1248/cpb.50.1479</pub-id>
          <pub-id pub-id-type="pmid">12419913</pub-id>
        </citation>
      </ref>
      <ref id="B3-molbank-2010-M657">
        <label>3.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Gribble</surname>
              <given-names>G.W.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and antitumor activity of ellipticine alkaloids and related compounds</article-title>
          <source>The Alkaloids</source>
          <person-group person-group-type="editor">
            <name>
              <surname>Brossi</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <publisher-name>Academic Press</publisher-name>
          <publisher-loc>New York, NY, USA</publisher-loc>
          <year>1990</year>
          <fpage>239</fpage>
          <lpage>352</lpage>
        </citation>
      </ref>
      <ref id="B4-molbank-2010-M657">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohashi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Oki</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Ellipticine and related anticancer agents</article-title>
          <source>Exp. Opin. Ther. Patents</source>
          <year>1996</year>
          <volume>6</volume>
          <fpage>1285</fpage>
          <lpage>1294</lpage>
          <pub-id pub-id-type="doi">10.1517/13543776.6.12.1285</pub-id>
        </citation>
      </ref>
      <ref id="B5-molbank-2010-M657">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haider</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Diazine analogues of the pyridocarbazole alkaloids</article-title>
          <source>Curr. Org. Chem.</source>
          <year>2006</year>
          <volume>10</volume>
          <fpage>363</fpage>
          <lpage>375</lpage>
          <pub-id pub-id-type="doi">10.2174/138527206775473913</pub-id>
        </citation>
      </ref>
      <ref id="B6-molbank-2010-M657">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haider</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Pyridazine-fused carbazoles: Synthesis, reactivity, and antitumor activity</article-title>
          <source>J. Heterocycl. Chem.</source>
          <year>2002</year>
          <volume>39</volume>
          <fpage>511</fpage>
          <lpage>521</lpage>
          <pub-id pub-id-type="doi">10.1002/jhet.5570390307</pub-id>
        </citation>
      </ref>
      <ref id="B7-molbank-2010-M657">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haider</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Kabicher</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>K&#xE4;ferb&#xF6;ck</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Plenk</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and <italic>in vitro</italic> antitumor activity of 1-[3-(indol-1-yl)prop-1-yn-1-yl]phthalazines and related compounds</article-title>
          <source>Molecules</source>
          <year>2007</year>
          <volume>12</volume>
          <fpage>1900</fpage>
          <lpage>1909</lpage>
          <pub-id pub-id-type="doi">10.3390/12081900</pub-id>
          <pub-id pub-id-type="pmid">17960095</pub-id>
        </citation>
      </ref>
      <ref id="B8-molbank-2010-M657">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haider</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Jbara</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>K&#xE4;ferb&#xF6;ck</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Traar</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of tetra- and pentacyclic carbazole-fused imides as potential antitumor agents</article-title>
          <source>Arkivoc</source>
          <year>2009</year>
          <fpage>38</fpage>
          <lpage>47</lpage>
        </citation>
      </ref>
      <ref id="B9-molbank-2010-M657">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pongprom</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Mueller</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Holzer</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Spreitzer</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Carbinol derivatives of azanaphthoquinone annelated pyrrols</article-title>
          <source>Monatsh. Chem.</source>
          <year>2009</year>
          <volume>140</volume>
          <fpage>309</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="doi">10.1007/s00706-008-0024-3</pub-id>
        </citation>
      </ref>
      <ref id="B10-molbank-2010-M657">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shanab</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Pongprom</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Wulz</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Holzer</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Spreitzer</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Aicher</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Mueller</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>G&#xFC;nther</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and biological evaluation of novel cytotoxic azanaphthoquinone annelated pyrrolo oximes</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2007</year>
          <volume>17</volume>
          <fpage>6091</fpage>
          <lpage>6095</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2007.09.054</pub-id>
          <pub-id pub-id-type="pmid">17904839</pub-id>
        </citation>
      </ref>
      <ref id="B11-molbank-2010-M657">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spreitzer</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Puschmann</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Dual function antitumor agents based on bioreduction and DNA alkylation</article-title>
          <source>Monatsh. Chem.</source>
          <year>2007</year>
          <volume>138</volume>
          <fpage>517</fpage>
          <lpage>522</lpage>
          <pub-id pub-id-type="doi">10.1007/s00706-007-0604-7</pub-id>
        </citation>
      </ref>
      <ref id="B12-molbank-2010-M657">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bertini</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Lucchesini</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Pocci</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>De Munno</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>3,5-Dichloro-4-pyridinecarbonitrile as a key reagent in a synthesis of copper containing amine oxidase inhibitors</article-title>
          <source>Heterocycles</source>
          <year>1995</year>
          <volume>41</volume>
          <fpage>675</fpage>
          <lpage>688</lpage>
          <pub-id pub-id-type="doi">10.3987/COM-94-6945</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
